- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| THIRD HARMONIC BIO Aktie jetzt für 0€ handeln | |||||
| 07.11. | Third Harmonic Flat on Q3 Results | - | Baystreet.ca | ||
| 07.11. | Third Harmonic Bio Announces Third Quarter 2024 Financial Results | 106 | GlobeNewswire (Europe) | THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO... ► Artikel lesen | |
| 07.11. | Third Harmonic Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | Third Harmonic Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 31.10. | BVF Partners verkauft Aktien von Third Harmonic Bio im Wert von 14,3 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 30.10. | Medizinischer Leiter von Third Harmonic Bio verkauft Aktien im Wert von 40.095 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.09. | Third Harmonic Bio executive sells shares worth over $71,000 | 2 | Investing.com | ||
| 10.09. | Third Harmonic Bio to Participate in Upcoming Investor Conferences in September | 1 | GlobeNewswire (USA) | ||
| 26.08. | Third Harmonic Bio to Participate in Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 09.08. | Morgan Stanley raises Third Harmonic Bio stock rating to Overweight | 2 | Investing.com | ||
| 08.08. | Third Harmonic Loses on Q2 Financials | - | Baystreet.ca | ||
| 08.08. | Third Harmonic Bio GAAP EPS of $0.46 | 1 | Seeking Alpha | ||
| 08.08. | Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update | 94 | GlobeNewswire (Europe) | THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million... ► Artikel lesen | |
| 08.08. | Third Harmonic Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | Third Harmonic Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 18.06. | Stifel starts Third Harmonic at buy, cites mast cell disease approach | 2 | Seeking Alpha | ||
| 07.06. | Third Harmonic Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 15.05. | Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update | 119 | GlobeNewswire (Europe) | U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H'25 Strengthened leadership... ► Artikel lesen | |
| 28.03. | Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors | 248 | GlobeNewswire (Europe) | SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,725 | -5,22 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,720 | -3,10 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,890 | -5,82 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 16,400 | +1,30 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,960 | +1,05 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,280 | +0,48 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,210 | -0,75 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,700 | -0,59 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,590 | +0,88 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,000 | 0,00 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 24,430 | +7,67 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,790 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
Das Unternehmen THIRD HARMONIC BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,250 (+2,15 %) liegt der Kurs bei 11,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THIRD HARMONIC BIO INC finden Sie auf Wallstreet Online.
